Artificial intelligence (AI)-assisted training improves pathologist accuracy in human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) scoring in patients with breast cancer.

Background: The advent of HER2-targeted antibody-drug conjugates and the introduction of HER2-low and HER2-ultralow diagnostic categories have made precise HER2 IHC assessment crucial for optimal ...

Discover which therapies are expected to grab the HER2-low cancers market share @ HER2-low Cancers Market Report The HER2-low ...

AI could help pathologists identify HER2-low and HER2-ultralow breast cancers with greater accuracy, according to findings scheduled for presentation at ASCO Annual Meeting.In a study of more than ...

Background: The emergence of novel therapeutic agents demonstrating improved progression-free survival (PFS) and overall survival (OS) in breast cancer patients with low HER2 expression underscores ...

Alphamab Oncology (stock code: 9966.HK) announced that multiple clinical data updates for anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 were presented as posters at the 2025 Annual ...

Thursday, June 19, 2025. News & Perspective Drugs & Diseases CME & Education Video Decision Point Drugs & Diseases CME & Education Video Decision Point ...

HER2 IHC of 3+ (vs. IHC 2+/ISH+) Use of weekly paclitaxel rather than every-3-week docetaxel; Higher HER2DX pCR score regardless of ER status; ...

In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 study for the treatment of patients with HER2-expressing, mismatch repair ...

AstraZeneca & Daiichi Sankyo’s Datroway gets US approval for patients with previously treated advanced EGFR-mutated NSCLC ...